{"schema_version":"secwatch.filing_event.v1","accession":"0001683168-24-001099","form_type":"8-K","ticker":"CNSP","cik":"0001729427","company_name":"CNS Pharmaceuticals, Inc.","filed_at":"2024-02-21T23:59:59+00:00","discovered_at":"2026-05-14T18:03:25.286732+00:00","generated_at":"2026-06-05T22:12:03.569173+00:00","sec_items":["3.01"],"event_type":"regulatory","sentiment":"negative","materiality_score":0.75,"calibrated_materiality_score":0.75,"confidence":"high","headline":"CNS Pharmaceuticals receives Nasdaq delisting notice over equity shortfall; will request hearing","bullets":["Nasdaq notified CNSP on Feb 14, 2024, that it failed to meet minimum $2.5M stockholders' equity requirement after extension expired.","Company intends to request a hearing before a Nasdaq Hearings Panel, which will automatically stay suspension or delisting pending the hearing.","Panel may grant an extension not to exceed August 12, 2024, but compliance is not assured.","Previous extension was granted until Feb 13, 2024; company still non-compliant."],"urls":{"canonical":"https://secwatch.observer/filing/0001683168-24-001099","json":"https://secwatch.observer/filing/0001683168-24-001099.json","markdown":"https://secwatch.observer/filing/0001683168-24-001099.md","text":"https://secwatch.observer/filing/0001683168-24-001099.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1729427/000168316824001099/0001683168-24-001099-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1729427/000168316824001099/cns_8k.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-05T22:12:03.569173+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[{"claim_id":"680ff0f9be30bafc03964fa92345a1b4064c55a1","claim":"CNS Pharmaceuticals, Inc. received a nasdaq noncompliance notice notice regarding stockholders equity (rules 5550(b)).","evidence_excerpt":"February 14, 2024, the Staff notified the Company that it had not complied with the Listing Rule and as such did not meet the terms of the extension. The Staff letter stated that unless the Company timely requests a hearing before a Hearings Panel (the “Panel”), the Company would be subject to delisting. Accordingly, the Company intends to timely request a hearing before the Panel. The hearing request will automatically stay any suspension or delisting action pending the hearing and the expiration of any additional extension period granted by the Panel following the hearing. In that regard, th","evidence_source":"SEC 8-K Item 3.01","evidence_url":"https://www.sec.gov/Archives/edgar/data/1729427/000168316824001099/0001683168-24-001099-index.htm","confidence":0.9,"family_label":"Listing & Compliance Notices","details":[{"label":"Exchange","value":"nasdaq"},{"label":"Notice","value":"noncompliance notice"},{"label":"Deficiency","value":"stockholders equity"},{"label":"Rules","value":"5550(b)"}],"fact_type":"exchange_compliance_notice"}],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}